Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Fierce 15 nominations are now open! We're looking for the best and brightest in biotech.
CymaBay Therapeutics
Biotech
Gilead liver disease med still delivers ahead of FDA verdict
Three months after spending $4.3 billion on CymaBay for its primary biliary cholangitis med, Gilead Sciences has presented a fresh slice of data.
James Waldron
May 20, 2024 8:30am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
Gilead pays $4.3B for CymaBay's late-stage liver disease med
Feb 12, 2024 9:01am
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
Nov 14, 2023 5:55am
CymaBay's liver drug improves biomarkers, itching in phase 3
Sep 7, 2023 10:15am
Roivant founder departs for White House bid—Chutes & Ladders
Feb 24, 2023 9:30am